Gottlieb Nomination As US FDA Chief Could Signal Changes To Generic Approval Process
Executive Summary
Former deputy commissioner will also likely push increased use of biomarkers and more flexibility in off-label communication, among other reforms.
You may also be interested in...
FDA Commissioner-Nominee Gottlieb Pressed More On Drug Development Than Industry Ties
Scott Gottlieb's industry connections were expected to be a major focus of his US Senate confirmation hearing. However, our analysis of the questions asked show drug development was the top priority.
'Repeal And Replace' Going Relatively Well For Pharma So Far
US White House game plan for repealing and replacing the Affordable Care Act includes a proposal for faster generic drug approvals but no direct government price controls.
Off-Label Wish List: Industry Groups Want US FDA's Guidances To Do More
Sponsors and payers question guidances' scope and potential audiences, and wonder if the agency couldn't just perform some retrospective audits of off-label communication to speed things up.